Exact Sciences
EXASNYSEUS Equity
$104.91▲ $0.00 (+0.00%)
Market closed · at close1h—
24h▲ 0.0%
7d▲ 0.0%
14d▲ 0.0%
30d▲ 0.0%
1y▲ 133.5%
🏦Market Cap
$355B
Large Cap
📈Revenue Growth (YoY)
+0.3%
Slowing
📊Gross Margin
63.8%
High
💵FCF Margin
11.2%
Healthy
⚖️P/S Ratio
9.2x
Elevated
Otter Score
52
Weak
Trading Snapshot
- Day Range
- $104.17 – $105.76
- 52-Week Range
- $103.90 – $208.67
- Volume
- $4.26B
- Avg Volume
- $4.22B
- Shares Outstanding
- 3.38B
- Next Earnings
- Oct 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $3.25B
- Last Q Revenue
- $878M
- P/E Ratio
- 24.4
- P/S Ratio
- 9.2x
- EPS (TTM)
- $7.07
- Dividend Yield
- 2.25%
Why Investors Own EXAS
- ✓High-growth profile — revenue up +0.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 64% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$3.25B▼ −4.1% YoY
Gross Margin (TTM)
63.8%▼ −0.4% YoY
Operating Income (TTM)
$1.20B▼ −4.1% YoY
Free Cash Flow (TTM)
$364M▼ −4.1% YoY
About Exact Sciences
A company profile for Exact Sciences isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
52/100
Analyst Ratings
ⓘConsensus
Hold
29 analysts
Strong Buy2
Buy6
Hold21
Sell0
Strong Sell0
Ratings as of Jul 2026
Latest News & Updates
🚀
Barron’s·2h ago
Exact Sciences tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift EXAS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
Exact Sciences announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.